Pfizer Says Off-Label Marketing FCA Suit Falls Short

By David McAfee (January 16, 2013, 7:19 PM EST) -- Pfizer Inc. asked a Massachusetts federal court on Tuesday to dismiss a False Claims Act whistleblower suit alleging that it improperly promoted off-label use of a schizophrenia drug, saying that the plaintiffs have failed to show that the drugmaker actually defrauded federal health care programs....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!